Video

Dr. Schwartz on the Results of the PACIFIC Trial

Author(s):

Gary Schwartz, MD

In Partnership With:

Gary Schwartz, MD, Baylor Scott & White Center for Thoracic Surgery, discusses the potential of single-agent durvalumab (Imfinzi) for the treatment of patients with stage III, locally advanced, unresectable non–small cell lung cancer (NSCLC).

Gary Schwartz, MD, Baylor Scott & White Center for Thoracic Surgery, discusses the potential of single-agent durvalumab (Imfinzi) for the treatment of patients with stage III, locally advanced, unresectable non—small cell lung cancer (NSCLC).

The trial, which was published in November in The New England Journal of Medicine, showed an incredible increase in disease-free survival and progression-free survival. It more than doubled in patients with stage III lung cancer who could not undergo surgery for a variety of reasons. Overall survival data are not yet mature.

Patients in the trial received either chemotherapy and radiation, which was considered definitive in that they were not going to have surgery afterwards, or chemotherapy and radiation followed by immunotherapy. Schwartz says there was an incredible survival benefit seen in those patients. He notes that patients did experience pneumonitis, which is somewhat concerning overall, but it is still too early to comment on.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Related Content
Ronan J. Kelly, MD, MBA, chief, oncology, Baylor Scott & White Health – North Texas; director, Baylor Scott & White Charles A. Sammons Cancer Center, Baylor University Medical Center; W.W. Caruth Jr. Endowed Chair of Immunology, Baylor University Medical Center
May 6th 2024

Agnostic Approval of Trastuzumab Deruxtecan Ushers in New Option for Advanced HER2+ Solid Tumors

Martin F. Dietrich, MD, PhD, medical oncologist, Cancer Care Centers of Brevard, The US Oncology Network, assistant professor, internal medicine, the University of Central Florida College of Medicine; Michelle Shiller, DO, cancer liaison physician, medical director, Genetics, assistant medical director, Baylor Scott & White Health in Dallas, medical director, Genomics and Molecular Pathology Services, PathGroup
June 27th 2024

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

Updates and Advances in Early Stage Breast Cancer
April 5th 2023

Updates and Advances in Early Stage Breast Cancer

Joyce O’Shaughnessy, MD
January 26th 2023

A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options

Edward J. Pearson, MD
December 22nd 2022

Evolution of Targeted Therapy Improves Clinical Benefit in Blood and Bone Marrow Cancers

Manali Kamdar, MD
December 11th 2021

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL